No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ATHE Alterity Therapeutics
- 1.7990
- -0.1010-5.32%
Close Jul 19 16:00 ET
15.93MMarket Cap-897P/E (TTM)
1.9500High1.7501Low56.93KVolume1.8700Open1.9000Pre Close106.61KTurnover0.71%Turnover RatioLossP/E (Static)8.86MShares5.410052wk High1.04P/B14.47MFloat Cap1.550052wk Low--Dividend TTM8.04MShs Float51.5000Historical High--Div YieldTTM10.52%Amplitude1.5500Historical Low1.8720Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Alterity Therapeutics Seeks ASX Quotation
Alterity Therapeutics Plans New Share Issue
Alterity Shares Rise After Phase 2 Multiple System Atrophy Trial Interim Data
Alterity Therapeutics (ATHE) shares rose 13.6% in recent Wednesday trading after the company said preliminary data from a phase 2 trial showed that its investigative drug ATH434 improved symptoms in
Express News | Trading Halt: Halt Status Updated at 9:05:00 AM ET: Quotation Resumption: News and Resumption Times
Express News | Alterity Therapeutics Announced Positive Interim Data From The ATH434-202 Open-label Phase 2 Clinical Trial In Patients With Multiple System Atrophy
Alterity Therapeutics' ATH434 Trial Results Suggest Improved Outcomes for MSA Patients
Comments
$Alterity Therapeutics(ATHE.US$ Benzinga· 1 min ago
Alterity Therapeutics Announced Positive Interim Data From The ATH434-202 Open-label Phase 2 Clinical Trial In Patients With Multiple System Atrophy
Alterity Therapeutics Announced Positive Interim Data From The ATH434-202 Open-label Phase 2 Clinical Trial In Patients With Multiple System Atrophy
2
$Alterity Therapeutics(ATHE.US$
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
Alterity Therapeutics (NASDAQ: ATHE) has reported positive interim data from its ATH434-202 Phase 2 clinical trial for multiple system atrophy (MSA). Key findings include:
▪️43% of participants showed improvement in daily living activities
29% had stable or improved neurological symptoms
▪️Objective biomarkers demonstrated improvement consist...
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
Alterity Therapeutics (NASDAQ: ATHE) has reported positive interim data from its ATH434-202 Phase 2 clinical trial for multiple system atrophy (MSA). Key findings include:
▪️43% of participants showed improvement in daily living activities
29% had stable or improved neurological symptoms
▪️Objective biomarkers demonstrated improvement consist...
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg